User profiles for Alison J. Holmes
 | Alison HolmesProfessor of Infectious Diseases Verified email at imperial.ac.uk Cited by 26455 |
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
…, X Zhao, J Christensen, T Kosaka, AJ Holmes… - science, 2007 - science.org
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are
effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably …
effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably …
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer
…, C Murphy, E Lifshits, AJ Holmes, HG Choi, J Kim… - Clinical cancer …, 2008 - AACR
Purpose: The EML4-ALK fusion gene has been detected in ∼7% of Japanese non-small cell
lung cancers (NSCLC). We determined the frequency of EML4-ALK in Caucasian NSCLC …
lung cancers (NSCLC). We determined the frequency of EML4-ALK in Caucasian NSCLC …
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or …
…, BY Yeap, LV Sequist, N Lindeman, AJ Holmes… - Clinical Cancer …, 2006 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been detected
in patients with non–small cell lung cancer (NSCLC) and are associated with sensitivity …
in patients with non–small cell lung cancer (NSCLC) and are associated with sensitivity …
Phase II clinical trial of chemotherapy-naive patients≥ 70 years of age treated with erlotinib for advanced non–small-cell lung cancer
…, AT Skarin, M Meyerson, AJ Holmes… - Journal of Clinical …, 2007 - ascopubs.org
Purpose This is a phase II, multicenter, open-label study of chemotherapy-naïve patients
with non–small-cell lung cancer (NSCLC) and age ≥ 70 years who were treated with erlotinib …
with non–small-cell lung cancer (NSCLC) and age ≥ 70 years who were treated with erlotinib …
[PDF][PDF] Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization–positive/phospho-Akt–positive or never smoker patients with …
…, E Rossi, R Trisolini, D Paioli, AJ Holmes… - Journal of Clinical …, 2007 - Citeseer
Purpose In non–small-cell lung cancer (NSCLC), clinical and biologic predictors for epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor sensitivity have been identified in …
growth factor receptor (EGFR) tyrosine kinase inhibitor sensitivity have been identified in …
Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex
W Qin, P Kozlowski, BE Taillon, P Bouffard, AJ Holmes… - Human genetics, 2010 - Springer
Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous syndrome
caused by mutations in TSC1 and TSC2. However, 10–15% TSC patients have no mutation …
caused by mutations in TSC1 and TSC2. However, 10–15% TSC patients have no mutation …
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?
…, SW Shin, JH Choi, CS Ki, CK Park, AJ Holmes… - Clinical cancer …, 2008 - AACR
Purpose: This study investigated possible molecular predictors of outcome in Korean patients
with advanced non-small cell lung cancer treated with erlotinib. Experimental Design: One …
with advanced non-small cell lung cancer treated with erlotinib. Experimental Design: One …
[HTML][HTML] Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non …
S Park, AJ Holmes-Tisch, YM Shim, J Kim… - Journal of Thoracic …, 2009 - Elsevier
Introduction: For the identification of the patients who most likely benefit from epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), …
growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC), …
Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers
LM Sholl, BY Yeap, AJ Iafrate, AJ Holmes-Tisch… - Cancer research, 2009 - AACR
In a subset of lung adenocarcinomas, the epidermal growth factor receptor (EGFR) is activated
by kinase domain mutations and/or gene amplification, but the interaction between the …
by kinase domain mutations and/or gene amplification, but the interaction between the …
Injectional anthrax infection due to heroin use induces strong immunological memory
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic
comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: …
comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: …